Aarti Pharmalabs Limited (IN:AARTIPHARM)
:AARTIPHARM
AARTIPHARM Stock Chart & Stats
₹842.40
₹9.55(1.45%)
At close: 4:00 PM EST
₹842.40
₹9.55(1.45%)
Day’s Range― - ―
52-Week Range₹583.85 - ₹971.50
Previous CloseN/A
Volume141.60K
Average Volume (3M)18.67K
Market Cap
₹61.81B
Enterprise Value₹67.77B
Total Cash (Recent Filing)₹555.56M
Total Debt (Recent Filing)₹6.59B
Price to Earnings (P/E)35.6
Beta0.82
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)5.29
Shares Outstanding90,657,750
10 Day Avg. Volume12,195
30 Day Avg. Volume18,670
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)3.43
Price to Sales (P/S)3.23
P/FCF Ratio-96.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹965.00Price Target Upside14.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a high equity ratio provide a durable financial cushion versus peers, reducing refinancing risk and supporting capital allocation. Improved ROE demonstrates more effective use of shareholder capital, enabling resilience through industry cycles and capacity to fund strategic investments.
Strong Margin ProfileElevated and improving gross and operating margins indicate structural cost control and pricing power in core API businesses. Sustained mid-teens EBIT/EBITDA margins support durable profitability, enhance internal cash generation potential, and provide buffers against raw-material swings.
B2B API Manufacturing ModelA focused B2B API and intermediates supplier benefits from structural demand in pharmaceutical manufacturing and recurring, contract-driven revenue. The business model favors long-term customer relationships, technical barriers to entry, and steady industrial demand versus consumer-facing cyclicality.
Bears Say
Negative Free Cash FlowPersistent negative FCF from elevated capex undermines financial flexibility, forcing reliance on external funding or slower deleveraging. Over the medium term this can constrain dividends, limit strategic investments, and magnify liquidity risk if cash conversion does not improve.
Earnings Decline / VolatilityA material decline in EPS indicates pressure on underlying profitability or one-off impacts that have not yet normalized. Continued EPS weakness can erode reinvestment capacity, limit retained earnings growth, and signal vulnerability to demand or margin shocks over coming quarters.
Input Cost And Product-mix ExposureProfitability depends on sustaining a favorable product mix and stable raw-material costs. Volatility in feedstock prices or weaker high-value API volumes can compress margins. Capacity-utilization sensitivity means fixed costs can amplify downturns, posing medium-term margin risk.
Aarti Pharmalabs Limited News
AARTIPHARM FAQ
What was Aarti Pharmalabs Limited’s price range in the past 12 months?
Aarti Pharmalabs Limited lowest stock price was ₹583.85 and its highest was ₹971.50 in the past 12 months.
What is Aarti Pharmalabs Limited’s market cap?
Aarti Pharmalabs Limited’s market cap is ₹61.81B.
When is Aarti Pharmalabs Limited’s upcoming earnings report date?
Aarti Pharmalabs Limited’s upcoming earnings report date is May 11, 2026 which is in 31 days.
How were Aarti Pharmalabs Limited’s earnings last quarter?
Aarti Pharmalabs Limited released its earnings results on Feb 09, 2026. The company reported ₹5.29 earnings per share for the quarter, beating the consensus estimate of N/A by ₹5.29.
Is Aarti Pharmalabs Limited overvalued?
According to Wall Street analysts Aarti Pharmalabs Limited’s price is currently Undervalued.
Does Aarti Pharmalabs Limited pay dividends?
Aarti Pharmalabs Limited pays a Semiannually dividend of ₹2.5 which represents an annual dividend yield of 0.67%. See more information on Aarti Pharmalabs Limited dividends here
What is Aarti Pharmalabs Limited’s EPS estimate?
Aarti Pharmalabs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarti Pharmalabs Limited have?
Aarti Pharmalabs Limited has 90,657,750 shares outstanding.
What happened to Aarti Pharmalabs Limited’s price movement after its last earnings report?
Aarti Pharmalabs Limited reported an EPS of ₹5.29 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.36%.
Which hedge fund is a major shareholder of Aarti Pharmalabs Limited?
Currently, no hedge funds are holding shares in IN:AARTIPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, new chemical entities, and xanthine derivatives in India. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India.
AARTIPHARM Stock 12 Month Forecast
Average Price Target
₹965.00
▲(14.55% Upside)
Technical Analysis
Aarti Drugs Limited
―
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Glenmark Pharmaceuticals Limited
―
Laurus Labs Ltd.
―